AUPH Aurinia Pharmaceuticals Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: AUPH

Price (delayed)

$16.97

Market cap

$2.18B

P/E Ratio

7.61

Dividend/share

N/A

EPS

$2.23

Enterprise value

$2.21B

?
Relative Growth: Rel. Growth: 87
Relative Strength: Rel. Strength: 79
Relative Valuation: Rel. Valuation: 87
Relative Profitability: Rel. Profitability: 99

Aurinia Pharmaceuticals is a fully integrated biopharmaceutical company focused on delivering therapies to treat targeted patient populations that are impacted by serious diseases with a high unmet medical need. The ...

Highlights
The P/E is 42% less than the last 4 quarters average of 13.1
Aurinia Pharmaceuticals's gross profit has increased by 23% YoY and by 7% from the previous quarter
AUPH's equity has soared by 62% year-on-year but it is down by 2.4% since the previous quarter
The quick ratio rose by 5% since the previous quarter but it has declined by 4.3% year-on-year
Sector: Healthcare
Industry: Biotechnology
Website: http://www.auriniapharma.com
Peers: QURE LXRX

Key stats

What are the main financial stats of AUPH

AUPH stock price

How has the Aurinia Pharmaceuticals stock price performed over time
Intraday
1.07%
1 week
-5.09%
1 month
10.7%
1 year
100.35%
YTD
6.39%
QTD
14.51%

Financial performance

How have Aurinia Pharmaceuticals's revenue and profit performed over time
Revenue
$298.3M
Gross profit
$267.7M
Operating income
$124.49M
Net income
$298.21M
Gross margin
89.7%
Net margin
100%
Aurinia Pharmaceuticals's gross profit has increased by 23% YoY and by 7% from the previous quarter
The revenue has increased by 21% YoY and by 5% from the previous quarter
The operating income is up by 19% since the previous quarter
The operating margin has increased by 12% from the previous quarter

Price vs fundamentals

How does AUPH's price correlate with its fundamentals

Growth

What is Aurinia Pharmaceuticals's growth rate over time

Valuation

What is Aurinia Pharmaceuticals stock price valuation
AUPH P/E details
P/E
7.61
P/B
3.98
P/S
7.53
EV/EBIT
16.01
EV/EBITDA
14.04
EV/Sales
7.41
The P/E is 42% less than the last 4 quarters average of 13.1
Aurinia Pharmaceuticals's EPS has increased by 4.2% QoQ
AUPH's equity has soared by 62% year-on-year but it is down by 2.4% since the previous quarter
The price to book (P/B) is 11% higher than the 5-year quarterly average of 3.6 and 11% higher than the last 4 quarters average of 3.6
The stock's P/S is 40% less than its 5-year quarterly average of 12.6 but 26% more than its last 4 quarters average of 6.0
The revenue has increased by 21% YoY and by 5% from the previous quarter

Efficiency

How efficient is Aurinia Pharmaceuticals business performance
AUPH's ROIC has soared by 155% year-on-year and by 5% since the previous quarter
Aurinia Pharmaceuticals's return on sales has surged by 146% YoY and by 11% QoQ
The ROE has decreased by 8% from the previous quarter
The company's return on assets fell by 5% QoQ

Dividends

What is AUPH's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for AUPH.

Financial health

How did Aurinia Pharmaceuticals financials performed over time
Aurinia Pharmaceuticals's total assets has increased by 43% YoY but it has decreased by 3.7% QoQ
The total liabilities has decreased by 8% from the previous quarter
Aurinia Pharmaceuticals's debt is 88% lower than its equity
AUPH's equity has soared by 62% year-on-year but it is down by 2.4% since the previous quarter
The company's debt to equity fell by 45% YoY and by 8% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.